Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37072571)

  • 1. Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies.
    Alhalabi O; Groisberg R; Zinner R; Hahn AW; Naing A; Zhang S; Tsimberidou AM; Rodon J; Fu S; Yap TA; Hong DS; Sun M; Jiang Y; Pant S; Shah AY; Zurita A; Tannir NM; Vikram R; Roszik J; Meric-Bernstam F; Subbiah V
    NPJ Precis Oncol; 2023 Apr; 7(1):37. PubMed ID: 37072571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.
    Subbiah V; Coleman N; Piha-Paul SA; Tsimberidou AM; Janku F; Rodon J; Pant S; Dumbrava EEI; Fu S; Hong DS; Zhang S; Sun M; Jiang Y; Roszik J; Song J; Yuan Y; Meric-Bernstam F; Naing A
    Cancer Res Commun; 2024 Feb; 4(2):378-387. PubMed ID: 38126764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers.
    Chon HS; Kang S; Lee JK; Apte SM; Shahzad MM; Williams-Elson I; Wenham RM
    BMC Cancer; 2017 Jun; 17(1):407. PubMed ID: 28595616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study.
    Bellmunt J; Maroto P; Bonfill T; Vazquez F; Perez-Gracia JL; Juanpere N; Hernandez-Prat A; Hernandez-Llodra S; Rovira A; Juan O; Rodriguez-Vida A
    Clin Genitourin Cancer; 2024 May; 22(5):102123. PubMed ID: 38905731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.
    Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Johnson S; Ozols RF
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):18-29. PubMed ID: 7544025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I dose escalation study of dual PI3K/mTOR inhibition by Sapanisertib and Serabelisib in combination with paclitaxel in patients with advanced solid tumors.
    Starks DC; Rojas-Espaillat L; Meissner T; Williams CB
    Gynecol Oncol; 2022 Sep; 166(3):403-409. PubMed ID: 35843739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors.
    Wheler J; Mutch D; Lager J; Castell C; Liu L; Jiang J; Traynor AM
    Oncologist; 2017 Apr; 22(4):377-e37. PubMed ID: 28275119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321.
    Zhao Y; Foster NR; Meyers JP; Thomas SP; Northfelt DW; Rowland KM; Mattar BI; Johnson DB; Molina JR; Mandrekar SJ; Schild SE; Bearden JD; Aubry MC; Adjei AA
    J Thorac Oncol; 2015 Jan; 10(1):172-80. PubMed ID: 25247339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma.
    McGregor BA; Xie W; Adib E; Stadler WM; Zakharia Y; Alva A; Michaelson MD; Gupta S; Lam ET; Farah S; Nassar AH; Wei XX; Kilbridge KL; Harshman L; Signoretti S; Sholl L; Kwiatkowski DJ; McKay RR; Choueiri TK
    JCO Precis Oncol; 2022 Feb; 6():e2100448. PubMed ID: 35171658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
    Dunn LA; Fury MG; Xiao H; Baxi SS; Sherman EJ; Korte S; Pfister C; Haque S; Katabi N; Ho AL; Pfister DG
    Ann Oncol; 2017 Oct; 28(10):2533-2538. PubMed ID: 28961834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of CT-2103, a polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid tumors.
    Nemunaitis J; Cunningham C; Senzer N; Gray M; Oldham F; Pippen J; Mennel R; Eisenfeld A
    Cancer Invest; 2005; 23(8):671-6. PubMed ID: 16377585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study.
    Leong S; Cohen RB; Gustafson DL; Langer CJ; Camidge DR; Padavic K; Gore L; Smith M; Chow LQ; von Mehren M; O'Bryant C; Hariharan S; Diab S; Fox NL; Miceli R; Eckhardt SG
    J Clin Oncol; 2009 Sep; 27(26):4413-21. PubMed ID: 19652058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
    Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
    Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, Pharmacokinetics, and Clinical Activity of Adavosertib in Combination with Chemotherapy in Asian Patients with Advanced Solid Tumors: Phase Ib Study.
    Kato H; de Souza P; Kim SW; Lickliter JD; Naito Y; Park K; Kumar S; Mugundu GM; Bang YJ
    Target Oncol; 2020 Feb; 15(1):75-84. PubMed ID: 32034630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group.
    Saloustros E; Nikolaou M; Kalbakis K; Polyzos A; Christofillakis C; Kentepozidis N; Pistamaltzian N; Kourousis C; Vamvakas L; Georgoulias V; Mavroudis D
    Clin Breast Cancer; 2018 Feb; 18(1):88-94. PubMed ID: 29153775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
    Gray HJ; Bell-McGuinn K; Fleming GF; Cristea M; Xiong H; Sullivan D; Luo Y; McKee MD; Munasinghe W; Martin LP
    Gynecol Oncol; 2018 Mar; 148(3):507-514. PubMed ID: 29352572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer.
    Kelly K; Pan Z; Murphy J; Huffman DH; Bunn PA
    Clin Cancer Res; 1997 Jul; 3(7):1117-23. PubMed ID: 9815791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy.
    Choueiri TK; Porta C; Suárez C; Hainsworth J; Voog E; Duran I; Reeves J; Czaykowski P; Castellano D; Chen J; Sedarati F; Powles T
    Oncologist; 2022 Dec; 27(12):1048-1057. PubMed ID: 36146944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma.
    Alva A; Daignault S; Smith DC; Hussain M
    Invest New Drugs; 2014 Feb; 32(1):188-94. PubMed ID: 24318901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a california cancer consortium phase I and molecular correlative study.
    Lara PN; Frankel P; Mack PC; Gumerlock PH; Galvin I; Martel CL; Longmate J; Doroshow JH; Lenz HJ; Lau DH; Gandara DR
    Clin Cancer Res; 2003 Oct; 9(12):4356-62. PubMed ID: 14555506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.